PS
SUPN icon

Principal Securities’s Supernus Pharmaceuticals SUPN Stock Holding History

Principal Securities’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-188
Closed -$8.98K – 3259
2025
Q3 		$8.98K Sell
188
-65
-26% -$2.62K ﹤0.01% 2760
2025
Q2 		$7.97K Buy
253
+23
+10% +$737 ﹤0.01% 2713
2025
Q1 		$8.32K Hold
230
– – ﹤0.01% 2596
2024
Q4 		$8.32K Buy
230
+2
+0.9% +$70 ﹤0.01% 2592
2024
Q3 		$7.11K Buy
228
+32
+16% +$999 ﹤0.01% 2559
2024
Q2 		$5.24K Sell
196
-11
-5% -$319 ﹤0.01% 2625
2024
Q1 		$7.06K Buy
207
+27
+15% +$804 ﹤0.01% 2487
2023
Q4 		$5.21K Buy
+180
New +$4.77K ﹤0.01% 2518

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Principal Securities's SUPN Position: Q4 2025 in Review

Principal Securities sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 188 shares — an estimated $8.98K sold.

Principal Securities first reported a position in SUPN in Q4 2023 and held it in 8 quarters. The position peaked at $8.98K in Q3 2025. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • Principal Securities reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 188 Supernus Pharmaceuticals shares in Q4 2025, an estimated $8.98K.
  • Principal Securities first reported a position in Supernus Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Supernus Pharmaceuticals position peaked at $8.98K in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.